Abstract
Neurodegeneration in Alzheimer’s disease (AD) entails dysregulated signalling in and between neurons. As such, the search for new therapies capable of normalising these signalling dysfunctions in AD is a promising strategy to treat the disease. Therefore we set out to validate an in-house high-throughput phenotypic screening system featuring AD-like signalling
... read more